Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 77Prostatic Neoplasms 56Carcinoma, Non-Small-Cell Lung 50Breast Neoplasms 49Esophageal Neoplasms 47Rectal Neoplasms 41Lung Neoplasms 40Squamous Cell Carcinoma of Head and Neck 32Gliosarcoma 31Head and Neck Neoplasms 30Brain Neoplasms 30Pancreatic Neoplasms 29Uterine Cervical Neoplasms 27Neoplasm Metastasis 23Glioma 23Neoplasms 22Oropharyngeal Neoplasms 20Esophageal Squamous Cell Carcinoma 20Sarcoma 19Melanoma 18Astrocytoma 17Adenocarcinoma Of Esophagus 15Stomach Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Carcinoma, Squamous Cell 12Urinary Bladder Neoplasms 11Lymphoma, Follicular 11Central Nervous System Neoplasms 11Carcinoma 11Burkitt Lymphoma 10

Interventions

abiraterone 1Specimen Handling 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1Gonadotropin-Releasing Hormone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Oligometastatic Prostate Carcinoma × Radiation × Clear all
NCT06369610 2025-11-14

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

Mayo Clinic

Phase 2 Recruiting
110 enrolled
Genitourinary

Oligometastatic Prostate Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡